We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
- Authors
Lenz, Georg; Dreyling, Martin; Hoster, Eva; Wörmann, Bernhard; Dührsen, Ulrich; Metzner, Bernd; Eimermacher, Hartmut; Neubauer, Andreas; Wandt, Hannes; Steinhauer, Hjalmar; Martin, Sonja; Heidemann, Else; Aldaoud, Ali; Parwaresch, Reza; Hasford, Joerg; Unterhalt, Michael; Hiddemann, Wolfgang
- Abstract
Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to improve outcome, the German Low Grade Lymphoma Study Group (GLSG) initiated a randomized trial comparing the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and rituximab (R-CHOP) with CHOP alone as first-line therapy for advanced-stage MCL.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 9, p1984
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.08.133